Abstract Details

Title Psychotherapeutic approach for the treatment of generalized anxiety disorder (GAD) improves outcome when delivered under specific (narrow band) green light condition.

Topic General Neurology

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 2-004

Objective To evaluate the impact of narrow-band green light (nbGL) on 45-min long sessions for the treatment of GAD by psychotherapists.

Background Studies in migraine patients revealed that during attacks, exposure to blue, red, amber, and white lights trigger negative emotions (e.g., feeling more stressed and upset), and that in contrast, exposure to nbGL induces positive emotions (e.g., feeling relaxed and calm). These finding raised the possibility that under this unique light condition, psychotherapy sessions for GAD could be more productive.

Design/Methods Within-subject (repeated measures) study design comparing effects of conducting 2 psychotherapy sessions under white light (WL) and 6 sessions under nbGL (delivered by Allay Lamp, Allay, USA) in patients’ self-evaluation of treatment using the State part (Y-1, Qs.1-20) of the State-Trait-Anxiety-Inventory questionnaire at the beginning and end of each session. Included in the analysis were 7 male and 6 female patients (18-72 y/o) diagnosed with GAD.

Results (a) Total score. WL = 42.5 (41-48.2) [median (IQR)] before vs. 42.5 (38-49.2) after (p=0.37). nbGL= 40.8 (37.3-46.5) before vs. 39.1 (37.6-45.5) after (p=0.70). (b) Reversed scored items (symptom-positively worded). WL= 2 (1-2.5) before vs. 2 (1.5-2.5) after (p=0.60). nbGL= 2 (1.3-2.5) before vs. 2.1 (1.5-2.6) after (p=0.007). (c) State anxiety-present items (symptom-negatively worded) WL= 2.5 (1.5-3.5) before vs. 2.2 (1.5-3) after (p=0.35). nbGL= 2 (1.3-2.8) before vs. 1.8 (1.3-2.6) after (p=0.001) (Wilcoxon rank sum test). Comparing between and within group analysis of the 4 conditions as independent variables using ANOVA and Post-hoc analysis for multiple comparison (Tukey HSD) revealed the following: (a) symptom-positively worded - differences between after nbGL vs. the other 3 variables were significant [ANOVA F=5.69, p=0.0008; Tukey HSD p<0.01). (b) symptom-negatively worded - differences between after nbGL vs. the other 3 variables were significant [ANOVA F=20.4, p=0.0002; Tukey HSD p<0.001).

Conclusions Using nbGL as an add-on to psychotherapy improves patients’ State of Anxiety.

Authors/Disclosures
Rami Burstein, PhD (Beth Isreal Deacones Medical Center) PRESENTER	Dr. Burstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Burstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dr. Reddy. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Percept. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Dr. Burstein has received research support from Allergan. The institution of Dr. Burstein has received research support from Teva. The institution of Dr. Burstein has received research support from Eli Lilly. The institution of Dr. Burstein has received research support from Dr. Reddy.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Agustin Melo Carrillo, MD, PhD (Beth Israel Deaconess Medical Center. Harvard Medical School)	Dr. Melo Carrillo has nothing to disclose.

��ɫ��

��ɫ��